A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Trametinib (Primary)
- Indications Haemangioendothelioma
- Focus Therapeutic Use
- 14 Dec 2018 Status changed from suspended to recruiting.
- 08 Oct 2018 Status changed from recruiting to suspended due to pending protocol amendment .
- 12 May 2017 New trial record